Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 19/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29638048 | 1.00 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL23803533 | 0.87 | RIPK1 (0.78) | RIPK1 | |
| SCHEMBL17882383 | 0.85 | RIPK1 (0.74) | RIPK1 | |
| SCHEMBL17874145 | 0.85 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL17874165 | 0.83 | RIPK1 (1.00) | RIPK1 | |
| SCHEMBL17882167 | 0.82 | RIPK1 (0.70) | RIPK1 | |
| SCHEMBL29912597 | 0.82 | RIPK1 (0.72) | RIPK1 | |
| SCHEMBL17874102 | 0.82 | RIPK1 (0.72) | RIPK1 | |
| SCHEMBL19448786 | 0.82 | RIPK1 (0.69) | RIPK1 | |
| SCHEMBL23803561 | 0.81 | RIPK1 (0.75) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | claimed |
| CN-110769853-B | Treatment of male aging | 北京生命科学研究所 | 2022-06-03 | — | — | CN | claimed |
| US-11090307-B2 | Treating male senescence | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2021-08-17 | — | — | US | claimed |
| CN-110769853-A | Treatment of male aging | 北京生命科学研究所 | 2020-02-07 | — | — | CN | claimed |
| EP-3224237-B1 | NECROSIS INHIBITORS | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-09-11 | — | — | EP | disclosed |
| EP-3612223-B1 | TREATING MALE SENESCENCE | NAT INSTITUTE OF BIOLOGICAL SCIENCES BEIJING (CN) | 2024-07-31 | — | — | EP | disclosed |
| CN-117320754-A | Prostatitis treatment | 北京生命科学研究所 | 2023-12-29 | — | — | CN | disclosed |
| CN-115197098-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2023-08-08 | — | — | CN | disclosed |
| CN-115197098-A | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-10-18 | — | — | CN | disclosed |
| US-20220288077-A1 | PROSTATITIS TREATMENT | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES (CN) | 2022-09-15 | — | — | US | disclosed |
| CN-107108467-B | Cell necrosis inhibitor | 北京生命科学研究所 | 2022-08-19 | — | — | CN | disclosed |
| EP-4017535-A1 | PROSTATITIS TREATMENT | National Institute Of Biological Sciences, Beijing (CN) | 2022-06-29 | — | — | EP | disclosed |
| US-20180263934-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-09-20 | — | — | US | disclosed |
| US-9974762-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-22 | — | — | US | disclosed |
| US-9974762-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-22 | — | — | US | disclosed |
| US-9974762-B2 | Necrosis inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2018-05-22 | — | — | US | disclosed |
| US-20170290790-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-12 | — | — | US | disclosed |
| US-20170290790-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-12 | — | — | US | disclosed |
| US-20170290790-A1 | Necrosis Inhibitors | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2017-10-12 | — | — | US | disclosed |
| WO-2016101885-A1 | NECROSIS INHIBITORS | NATIONAL INSTITUTE OF BIOLOGICAL SCIENCES, BEIJING (CN) | 2016-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11090307-B2 | Treating male senescence | RIPK3, RIPK1, MLKL | RIPK1 2/4885 |
| US-20170290790-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885 |
| US-20180263934-A1 | Necrosis Inhibitors | RIPK3, RIPK1, RIPK4 | RIPK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.